MDB Capital (NASDAQ:MDBH) Shares Up 3.5% – Should You Buy?

MDB Capital Holdings, LLC (NASDAQ:MDBHGet Free Report)’s stock price rose 3.5% on Thursday . The company traded as high as $2.95 and last traded at $2.95. 681 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 2,484 shares. The stock had previously closed at $2.85.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of MDB Capital from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Read Our Latest Analysis on MDB Capital

MDB Capital Stock Down 1.9%

The stock has a 50-day simple moving average of $3.15 and a 200-day simple moving average of $3.22. The firm has a market capitalization of $29.82 million, a PE ratio of -1.33 and a beta of 1.20.

Institutional Investors Weigh In On MDB Capital

Several large investors have recently added to or reduced their stakes in MDBH. Citadel Advisors LLC purchased a new stake in MDB Capital during the third quarter valued at about $43,000. DRW Securities LLC bought a new stake in shares of MDB Capital in the fourth quarter valued at approximately $40,000. Finally, Raymond James Financial Inc. bought a new stake in shares of MDB Capital in the second quarter valued at approximately $27,000. Hedge funds and other institutional investors own 0.35% of the company’s stock.

About MDB Capital

(Get Free Report)

MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business.

Featured Stories

Receive News & Ratings for MDB Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDB Capital and related companies with MarketBeat.com's FREE daily email newsletter.